Sotsiaalministeerium · 10. juuni 2021
Sisu (failidest)
Best-ReMaP Joint Action
Joint Action on Implementation of Validated Best Practices in Nutrition
Consortium Agreement
No. 631 - 81 / 2020 - 6 (323)
May 2021
Ljubljana, 31st of May 2021
Best-ReMaP JA Consortium Agreement 31st of May 2021
Table of Contents
Section 1: Definitions .............................................................................................................................. 6
Section 2: Purpose .................................................................................................................................. 9
Section 3: Entry into force, duration and termination .......................................................................... 9
Section 4: Responsibilities of beneficiaries.......................................................................................... 10
Section 5: Liability towards each other................................................................................................ 12
Section 6: Governance structure .......................................................................................................... 13
Section 7: Financial provisions ............................................................................................................. 18
Section 8: Results .................................................................................................................................. 20
Section 9: Access Rights ........................................................................................................................ 23
Section 11: Non-disclosure of information .......................................................................................... 26
Section 12: Miscellaneous .................................................................................................................... 28
Section 13: Signatures .......................................................................................................................... 29
Attachment 1: Background included ................................................................................................... 54
Attachment 2: Accession document .................................................................................................... 56
2
Best-ReMaP JA Consortium Agreement 31st of May 2021
Consortium Agreement
This Consortium Agreement is based upon the Grant Agreement between the Agency1, acting under
powers delegated by the Commission of the European Communities (“EC”) and the beneficiaries of
this Grant Agreement (Grant Agreement Number – 951202) concerning the action
“Joint Action on Implementation of Validated Best Practices in Nutrition”
hereinafter referred to as “Joint Action” or “JA” or “Best-ReMaP JA”
laying down the rules for the participation and dissemination in the 3rd Health Programme (2014-
2020)” (hereinafter referred to as “the Rules”), the EU Action Plan on childhood obesity 2014 – 2020
of 24 February 2014 and the European Commission Multi-beneficiary General Model Grant Agreement
and its Annexes,
and is effective as of 1 October 2020 hereinafter referred to as “the starting date of Joint Action” and
the “Effective Date”
BY AND AMONG:
1. The Coordinator, NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ)
Trubarjeva cesta 2,
1000 Ljubljana, Slovenia,
VAT number: SI44724535,
represented for the purposes of signing the Agreement by Director Milan Krek
and the following other beneficiaries, if they sign their “Accession Form” (see Annex 3 and Article 40
of the Grant Agreement):
2. BUNDESMINISTERIUM FUER SOZIALES, GESUNDHEIT, PFLEGE UND KONSUMENTENSCHUTZ
(BMSGPK)
Radetzkystrasse 2
Wien 1030, Austria
ATU38680502
3. SCIENSANO (SCIENSANO)
Juliette Wytsmanstraat 14
Elsene 1050, Belgium
VAT number: BE069387830
4. THE MINISTRY OF CIVIL AFFAIRS (MCA)
Trg Bosne i Hercegovine 1
Sarajevo 71000, Bosnia and Herzegovina
1
For the purpose of this Consortium Agreement the term “the Agency” will collectively be used to refer to Consumers, Health, Agriculture
and Food Executive Agency (CHAFEA), with whom the beneficiaries have entered into the Grant Agreement Nr. 951202 and European Health
and Digital Executive Agency (HaDEA) or other Agency, acting as a Funding Authority, under powers delegated by the Commission of the
European Communities (“EC”).
3
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
5. NATSIONALEN CENTAR PO OBSHTESTVENO ZDRAVE I ANALIZI (NCPHA)
ACAD IVAN GESHOV BLVD 15,
Sofia 1431, Bulgaria
VAT number: BG176094665
6. HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO (CIPH)
ROCKEFELLEROVA 7
Zagreb 10000, Croatia
VAT number: HR75297532041
7. Ministry of Health of the Republic of Cyprus (MoH CY)
1 Prodromou Street & 17 Chilonos Street
Nicosia 1448, Cyprus
8. FODEVARESTYRELSEN (DVFA)
STATIONSPARKEN 31
GLOSTRUP 2600, Denmark
VAT number: DK62534516
9. SOTSIAALMINISTEERIUM (MoSA)
Suur-Ameerika 1
Tallinn 10122, Estonia
VAT number: EE100535271
10. TERVEYDEN JA HYVINVOINNIN LAITOS (THL)
MANNERHEIMINTIE 166
Helsinki 00271, Finland
VAT number: FI22295006
11. AGENCE NATIONALE DE SECURITE SANITAIRE DE L ALIMENTATION DE L ENVIRONNEMENT ET
DU TRAVAIL (ANSES)
14 RUE PIERRE ET MARIE CURIE
MAISONS ALFORT 94700, France
VAT number: FR54130012024
12. MAX RUBNER INSTITUT BUNDESFORSCHUNGSINSTITUT FUR ERNAEHRUNG UND
LEBENSMITTEL (MRI)
HAID UND NEU STRASSE 9
KARLSRUHE 76131, Germany
VAT number: DE811393840
13. INSTITOUTON YGEIAS TOU PAIDIOU (ICH)
Thivon & Papadiamantopoulou 1,
ATHENS 11527, Greece
VAT number: EL090073098
4
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
14. SEMMELWEIS EGYETEM (SU)
ULLOI UT 26
BUDAPEST 1085, Hungary
VAT number: HU15329808
Responsible organisational unit: Health Services Management Training Centre
Represented by: Dr. Béla Merkely, Rector and Dr. Lívia Pavlik, Chancellor jointly
15. DEPARTMENT OF HEALTH (DoH)
Block 1, Miesian Plaza, 50-58 Lower Baggot Street
Dublin D02 XW14, Ireland
16. ISTITUTO SUPERIORE DI SANITA (ISS)
VIALE REGINA ELENA 299,
ROMA 00161, Italy
VAT number: IT03657731000
17. SLIMIBU PROFILAKSES UN KONTROLES CENTRS (CDPC)
Duntes 22, K-5
Riga LV1005, Latvia
VAT number: 90009756700
18. LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA (LR SAM)
VILNIAUS G 33
VILNIUS LT 01506, Lithuania
19. Ministry for Health - Government of Malta (MFH)
Palazzo Castellania, Merchants Street 15
Valletta VLT 200, Malta
VAT number: MT12979127
20. The State of the Netherlands, represented by its Minister of Health, Welfare and Sport, on
behalf of the Minister represented by Prof. dr. ir. J. Brug, Director-General of the National
Institute for Public Health and the Environment (Rijksinstituut voor Volksgezondheid en
Milieu) (RIVM)
Antonie van Leeuwenhoeklaan 9
3721 MA Bilthoven, the Netherlands,
VAT number: NL821772302B01 (“RIVM”)
21. SLASKI UNIWERSYTET MEDYCZNY W KATOWICACH (SUM)
UL. PONIATOWSKIEGO 15,
KATOWICE 40 055, Poland
VAT number: PL6340005301
22. MINISTERIO DA SAUDE - REPUBLICA PORTUGUESA (DGS)
Av. João Crisóstomo, 9
1049-062 Lisboa, Portugal
23. INSTITUTUL NATIONAL DE SANATATE PUBLICA (NIPH)
STR DR LEONTE 1-3 SECTOR 5
BUCURESTI 050463, Romania
5
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
24. INSTITUT ZA ZASTITU ZDRAVLJA SRBIJEDR MILAN JOVANOVIC BATUT (IPHS)
DR SUBOTICA STREET 5
Beograd 11000, Serbia
VAT number: RS102000930
hereinafter, jointly or individually, referred to as “beneficiaries” or ”beneficiary”, relating to the Joint
Action entitled “Joint Action on Implementation of Validated Best Practices in Nutrition ”, in short
Best-ReMaP JA.
Best-ReMaP JA shall run for 36 months from October 1, 2020 hereinafter referred to as “the starting
date of Joint Action” and the “Effective Date”.
WHEREAS:
The beneficiaries, having considerable experience in the field concerned, have submitted a proposal for
the Project to the Funding Authority as part of the 3rd EU Health Programme (2014-2020).
The beneficiaries wish to specify or supplement binding commitments among themselves in addition to
the provisions of the Grant Agreement number 951202 signed by the beneficiaries and the EC (hereinafter
“Grant Agreement” and “GA”). Best ReMaP JA is funded by the European Union’s Health Programme
(2014-2020).
The beneficiaries are aware that this Consortium Agreement is based upon the DESCA model consortium
agreement and modified according to the Grant Agreement.
NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:
Section 1: Definitions
1.1 Definitions
Words beginning with a capital letter shall have the meaning defined either herein or in the Rules or
in the Grant Agreement including its Annexes.
1.2 Additional Definitions
“Access Rights”
Access rights means rights to use Results or Background under the terms and conditions laid down in
accordance with this Consortium agreement.
“Affiliated entities”
See Grant Agreement Article 11.1, and Article 187, of the Regulation (EU, Euratom) 2018/1046 of the
European Parliament and of the Council of 18 July 2018 on the financial rules applicable to the general
budget of the Union (herein after referred to as the Regulation (EU, Euratom) 2018/1046) – entities
affiliated to the beneficiary are:
6
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
(a) entities that form a ‘sole beneficiary’ (i.e. where an entity is formed of several entities that
satisfy the criteria for being awarded a grant, including where the entity is specifically
established for the purpose of implementing an action to be financed by a grant);
(b) entities that satisfy the eligibility criteria and that do not fall within one of the situations
referred to in Articles 136(1) and 141(1) of the Regulation (EU, Euratom) 2018/1046 and that
have a link with the beneficiary, in particular a legal or capital link, which is neither limited to
the action nor established for the sole purpose of its implementation.
“Associated Partner”
An Associated Partner has a contractual relationship with the Agency and appears on the Grant
Agreement, even though mandating the Coordinator to sign it.
“Background”
Background means any data, know-how or information — whatever its form or nature (tangible or
intangible), including any rights such as intellectual property rights — that:
(a) is held by the beneficiaries before they acceded to the Agreement, and
(b) is needed to implement the action or exploit the results. (Background corresponds to pre-existing
rights in Grant Agreement article 19.1)
Background used within the scope of the Joint Action is defined in Attachment 1.
“Beneficiary”
Beneficiary or beneficiaries means a beneficiary or the beneficiaries to this Consortium Agreement also
identified as the beneficiaries to the Grant Agreement.
“Collaborating Partner”
A Collaborating Partner provides added value to the Joint Action and participates in the Joint Action
together with the Coordinator and Associated Partners, but has no contractual relationship with the
Agency. A Collaborating Partner carries no legal link to the JA and does not receive any EU funding.
“Competent Authority”
Competent Authority means the central authority nominated by the Member State which has signed
the Grant Agreement as beneficiary of EU Funding.
“Consortium Body”
Consortium Body means any structure of the Consortium, i.e. either General Assembly or Steering
Committee.
“Data”
Data means any and all data which is part of a beneficiary’s Background included in the Joint Action or
which is generated under the Joint Action as “results”, including, as the case may be, personal data as
defined and protected under the European or national applicable legislation(s).
7
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
“Dissemination”
Dissemination means the public disclosure of the results by any appropriate means (other than
resulting from protecting or exploiting the results), including by scientific publications in any medium.
“Exploitation”
Exploitation means the use of results in further research activities other than those covered by the
Joint Action concerned, or in developing, creating and marketing a product or process, or in creating
and providing a service, or standardisation activities.
“Fair and reasonable conditions”
Fair and reasonable conditions means appropriate conditions, including possible financial terms or
royalty-free conditions, taking into account the specific circumstances of the request for access, for
example the actual or potential value of the results or background to which access is requested and/or
the scope, duration or other characteristics of the exploitation envisaged.
“Foreground” means the results, including namely, but not exclusively, all documents, recommendations,
guidelines, information, materials and knowledge, generated within the project or as a result of it. It
includes all intellectual property rights (such as, but not limited to, the rights resulting from copyright
protection, related rights, design rights, patent rights) and knowhow.
“Funding Authority”
Funding Authority means the body awarding the grant for the Joint Action.
“Data Protection Laws”
Data Protection Laws means all applicable legislation concerning the protection of personal data, including
the Regulation (EU) 2016/679 Of The European Parliament And Of The Council of 27 April 2016 on the
protection of natural persons with regard to the processing of personal data and on the free movement
of such data, and repealing Directive 95/46/EC (hereinafter referred to as General Data Protection
Regulation or ”GDPR”), any other data protection legislation applicable to the Joint Action, as well as the
binding orders of data protection authorities.
“Defaulting beneficiary”
Defaulting beneficiary means a beneficiary which the majority of the Steering Committee has identified to
be in breach of this Consortium Agreement and/or the Grant Agreement as specified in Section 4.4 of this
Consortium Agreement.
“Needed”
For the implementation of the Joint Action:
Access Rights are Needed if, without the grant of such Access Rights, carrying out the tasks assigned to the
recipient beneficiary would be impossible, significantly delayed, or require significant additional financial
or human resources.
For exploitation of own Results: Access Rights are needed if, without the grant of such Access Rights, the
Exploitation of own Results would be technically or legally impossible.
8
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
“Results”
Results means any tangible or intangible output of the Joint Action, such as data, knowledge or
information, that is generated in the Joint Action, whatever its form or nature, whether or not it can
be protected, as well as any rights attached to it, including intellectual property rights.
Section 2: Purpose
The purpose of this Consortium Agreement is to specify with respect to the Joint Action the
relationship among the beneficiaries, in particular concerning the organisation of the work between
the beneficiaries, the management of the Joint Action and the rights and obligations of the
beneficiaries concerning inter alia liability, Access Rights and dispute resolution.
Section 3: Entry into force, duration and termination
3.1 Entry into force
An entity becomes a beneficiary to this Consortium Agreement upon signature of this Consortium
Agreement by a duly authorised representative.
This Consortium Agreement shall come into force at the date of its signature by the beneficiaries and shall
have retroactive effect as of 1 October 2020.
An additional entity becomes a beneficiary to the Consortium Agreement upon signature of the
accession document (Attachment 2) by the new beneficiary and the Coordinator. Such accession shall
have effect from the date identified in the accession document.
3.2 Duration and termination
This Consortium Agreement shall continue in full force and effect until complete fulfilment of all
obligations undertaken by the beneficiaries under the Grant Agreement and under this Consortium
Agreement.
However, this Consortium Agreement or the participation of one or more beneficiaries to it may be
terminated in accordance with the terms of this Consortium Agreement.
If the Grant Agreement
- is not signed by the Funding Authority or a beneficiary, or
- is terminated,
- or if a beneficiary's participation in the Grant Agreement is terminated,
this Consortium Agreement shall automatically terminate in respect of the affected beneficiary/ies,
subject to the provisions surviving the expiration or termination under Section 3.3 of this Consortium
Agreement.
9
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
3.3 Survival of rights and obligations
The provisions relating to Access Rights, Dissemination and Confidentiality, for the time period mentioned
therein, as well as for liability, applicable law and settlement of disputes shall survive the expiration or
termination of this Consortium Agreement.
Termination shall not affect any rights or obligations of a beneficiary leaving the Consortium incurred
prior to the date of termination, unless otherwise agreed between the Steering Committee and the
leaving beneficiary. This includes the obligation to provide all input, deliverables and documents for
the period of its participation.
Section 4: Responsibilities of beneficiaries
4.1 General principles
As health enablers, beneficiaries hereby undertake to advocate for the development of good practices
in nutrition, with due respect and in accordance with public health policies. Within the Best-ReMaP JA
any cooperation and communication with stakeholders should be taken under the public health driven
agenda, recognizing transparency as one of the general principles.
Each beneficiary undertakes to take part in the efficient implementation of the Best-ReMaP JA, and to
cooperate, perform and fulfil, promptly and on time, all of its obligations under the Grant Agreement
and this Consortium Agreement as may be reasonably required from it and in a manner of good faith
as prescribed by the applicable EU law, supplemented if necessary by the law of Belgium.
Each beneficiary undertakes to notify promptly the Coordinator about any significant information, fact,
problem or delay likely to affect the Joint Action.
Each beneficiary shall promptly provide all information reasonably required by a Consortium Body or by
the Coordinator to carry out its tasks.
Each beneficiary shall take reasonable measures to ensure the accuracy of any information or materials
it supplies to the other beneficiaries.
Each beneficiary shall act in accordance with the requirements of the Data Protection Laws. Each
beneficiary is responsible for ensuring that the processing of the data carried out by it is in accordance
with the Data Protection Laws and in accordance with Section 10 of this Agreement.
4.2 Beneficiaries
Beneficiaries are the competent authorities nominated by the participating countries. They must:
- Keep information stored in the Participant Portal Beneficiary Register (in the electronic exchange
system) up to date (see Article 12 of the Grant Agreement);
- Inform the Coordinator immediately of any events or circumstances likely to affect significantly
or delay the implementation of the action (see Article 12 of the Grant Agreement);
10
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
- Discuss any proposed activities which are not part of the Grant Agreement and annual work plans,
i.e. need an amendment, first with the WP lead, who can propose the changes to the Coordinator.
- Submit to the Coordinator in good time:
o Individual financial statements for itself and its affiliated entities (if applicable) and, if
required, certificates on the financial statements (see Article 15 of the Grant Agreement);
o The data needed to draw up all requested reports under Article 15 of the Grant
Agreement;
o If applicable, ethics committee opinions and notifications or authorisations for activities
raising ethical issues;
o Submit financial progress reports to the Coordinator in accordance with Section 7;
o Any other document(s) or information required by the Agency or the Commission under
the Grant Agreement, unless the Grant Agreement requires the beneficiary to submit this
information directly to the Agency or the Commission.
In addition, work package (WP) leaders are obliged to:
- Submit technical reports to the Coordinator in accordance with Section 7;
- Monitor the effective and efficient implementation of the WP;
- Discuss any proposed activities which are not part of the Grant Agreement and annual work plans,
i.e. need an amendment, with the Coordinator.
4.3 Involvement of third parties
A beneficiary that enters into a subcontract or otherwise involves third parties (including but not
limited to affiliated entities defined in the Grant Agreement Article 11) in the Joint Action remains
responsible for carrying out its relevant part of the Joint Action and for such third party’s compliance
with the provisions of the Grant Agreement. It has to ensure that the involvement of third parties does
not affect the rights and obligations of the beneficiaries under this Consortium Agreement and the
Grant Agreement.
In addition, affiliated entities are obliged to:
- Keep information stored in the Participant Portal Beneficiary Register (in the electronic
exchange system) up to date (see Article 12 of the Grant Agreement).
4.4 Breach
In the event that the Steering Committee identifies a breach by a beneficiary of its obligations under this
Consortium Agreement or the Grant Agreement (e.g. improper implementation of the Joint Action), the
Coordinator or, if the Coordinator is in breach of its obligations, the beneficiary appointed by the Steering
Committee, will give formal notice to such beneficiary requiring that such breach will be remedied within
30 calendar days from the date of receipt of the written notice by the beneficiary.
11
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
If such breach is substantial and is not remedied within that period or is not capable of remedy, the
Steering Committee may decide to declare the beneficiary to be a Defaulting beneficiary and to decide
on the consequences thereof which may include termination of its participation.
4.5 Compliance
Each beneficiary shall ensure that its work on the Joint Action complies fully with all applicable local,
government and international laws, regulations and guidelines which are effective during the period
of the Grant Agreement, including those governing health and safety and data protection.
Section 5: Liability towards each other
5.1 No warranties
In respect of any information or materials, incl. Results (Grant Agreement Article 19) and Background,
supplied by one beneficiary to another under the Joint Action, no warranty or representation of any kind
is made, given or implied as to the sufficiency or fitness for purpose nor as to the absence of any
infringement of any proprietary rights of third parties. This does not apply to Subsection 9.2.1.
Therefore,
- the recipient beneficiary shall in all cases be entirely and solely liable for the use to which it puts
such information and materials, and
- no beneficiary granting Access Rights shall be liable in case of infringement of proprietary rights
of a third party resulting from any other beneficiary (or its affiliated entities) exercising its Access
Rights.
5.2 Limitations of contractual liability
No beneficiary shall be responsible to any other beneficiary for any indirect or consequential loss or similar
damage such as, but not limited to, loss of profit, loss of revenue or loss of contracts, provided such
damage was not caused by a wilful act or gross negligence or by a breach of confidentiality.
For any remaining contractual liability, a beneficiary’s aggregate liability towards the other beneficiaries
collectively shall be limited to once the beneficiary’s share of the total costs of the Joint Action as identified
in Annex 2 of the Grant Agreement provided such damage was not caused by a wilful act or gross
negligence.
The terms of this Consortium Agreement shall not be construed to amend or limit any beneficiary’s
statutory liability.
5.3 Damage caused to third parties
12
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Each beneficiary shall be solely liable for any loss, damage or injury to third parties resulting from the
performance of the said beneficiary’s obligations by it or on its behalf under this Consortium Agreement
or from its use of Results or Background.
5.4 Force Majeure
No beneficiary shall be considered to be in breach of this Consortium Agreement if it is prevented from
fulfilling its obligations under the Consortium Agreement by Force Majeure (as defined in Article 35 of the
Grant Agreement).
Each beneficiary will notify the competent Consortium Bodies of any Force Majeure without undue delay.
If the consequences of Force Majeure for the Joint Action are not overcome within 6 weeks after such
notification, the transfer of tasks - if any - shall be decided by the Steering Committee.
Section 6: Governance structure
6.1 General structure
The organisational structure of the Consortium shall comprise the following Consortium Bodies:
Project Management Team (PMT) as an internal working group of administrative, financial and
scientific support within NIJZ.
Steering Committee (SC) is the main oversight committee of the Joint Action.
General Assembly (GA) meetings consisting of representatives of all Associated Partners and the PMT,
with Collaborating Partners and possibly other related projects and initiatives invited. The meetings
will be held to discuss progress on JA objectives with the entire Associated Partner consortium.
Policy decision making forum (PDMF) as a policy advisory board to the JA, will be informed on the JA
progress and proposals of the institutionalised / legislative solutions and asked for
comments/feedback with regard to the policy implementation options for the JA Best-ReMaP outputs.
Coordinator is the legal entity acting as the intermediary between the Parties and the Funding
Authority. The Coordinator shall, in addition to its responsibilities as a Party, perform the tasks assigned
to it as described in the Grant Agreement and this Consortium Agreement.
6.2 General operational procedures for all Consortium Bodies
6.2.1 Representation in meetings
Any beneficiary which is a member of a Consortium Body (hereinafter referred to as "Member"):
- should be represented at any meeting of such Consortium Body;
- may appoint a substitute or a proxy to attend and vote at any meeting;
- and shall participate in a cooperative manner in the meetings.
13
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
6.2.2 Preparation and organisation of meetings
The Coordinator shall convene meetings of all Consortium Bodies.
Ordinary meeting
Project Management Team At least once a week
Work Package Leaders Monthly meetings with PMT
Steering Committee At least six times during the course of the JA
General Assembly Four GA meetings over the course of the JA
Policy Decision Making Forum Three PDMF meetings are planned within the JA
The Coordinator shall give notice in writing of a meeting to each Member of that Consortium Body as
soon as possible and no later than the minimum number of days preceding the meeting as indicated
below.
Ordinary meeting
Steering Committee 21 calendar days
General Assembly 30 calendar days
Policy Decision Making Forum 30 calendar days
Any decision may also be taken without a meeting if the Coordinator circulates to all Members of the
Consortium Body a written document (e-mail) which is then agreed by all Members of the Consortium
Body. Such document shall include an appropriate deadline (minimum 7 calendar days) for responses.
Non-response within the deadline and after sending a written reminder including a grace period
(minimum 7 calendar days) shall be considered as agreement provided that the document has been
sent to an address given to the Coordinator by each Member. The decisions will be binding after the
Coordinator sends written notification of acceptance to all Members of the Consortium Body.
Meetings of each Consortium Body may also be held by teleconference or other telecommunication
means.
Decisions will only be binding once the relevant part of the Minutes has been accepted according to
Section 6.2.4.
6.2.3 Voting rules
Consortium bodies shall aim to achieve decisions through a consensus approach. This approach entails
discussion that aims to achieve consensus among members in order to promptly resolve the issues at
hand. Even if a unanimous decision cannot be reached, a group discussion where everyone's opinions
14
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
are heard and regarded shall take place, resulting in establishing the best solution that the Consortium
Body can achieve at a given time.
6.2.4 Minutes of meetings
6.2.4.1 The Coordinator shall produce written minutes of each meeting which shall be the formal
record of all decisions taken. The Coordinator shall send the draft minutes to all Members within 21
calendar days of the meeting.
The previous paragraph does not apply for the PDMF Meeting minutes.
6.2.4.2 The minutes shall be considered as accepted if, within 10 calendar days from sending, no
Member has sent an objection in writing to the Coordinator with respect to the accuracy of the draft
of the minutes.
6.2.4.3 The Coordinator shall safeguard the accepted minutes and send them to all the Members of
the Consortium Body.
6.3 Specific operational procedures for the Consortium Bodies
6.3.1 Project Management Team (PMT)
In addition to the rules in Section 6.2, the following rules apply:
6.3.1.1 Members
The Project Management Team shall consist of the Scientific Coordinator, Project Manager, Financial
Officer, Secretariat, Communications Officer, Legal Officer and researchers.
6.3.1.2 Tasks
- The Project Management Team shall discuss and resolve daily management issues.
- It shall act as liaison between all Associated Partners and the Agency.
- The Project Management Team shall communicate with the WP Leaders, Associated and
Collaborating Partners via a variety of methods. These include, but are not limited to: e-mail,
telephone, tele-, web- and videoconference, face to face meetings. Emphasis will be put on
regular bilateral web-conferences between the PMT and individual WPs, as well as online SC
meetings.
Key documents to be produced include: Project Policy, Financial Policy, Consortium Agreement,
Interim and Final Reports.
6.3.2 Steering Committee (SC)
In addition to the rules described in Section 6.2, the following rules apply:
15
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
6.3.2.1 Members
The Steering Committee shall consist of the Work Package leaders, Project Management Team and
representatives of the European Commission (hereinafter SC Members). The SC will be supported by
academic experts from relevant scientific fields, such as agri-food chain, national level public food
procurement, experts with specific knowledge on child legislation, as well as experts on health
inequalities.
The Coordinator shall chair all meetings of the Steering Committee.
6.3.2.2 Tasks
- The Steering Committee shall monitor the effective and efficient implementation of the Joint
Action and accept action plans on specific issues, where needed;
- It shall discuss all issues, which bear on the implementation of the JA, both in the realm of
scientific issues as well as administrative issues;
- The Steering Committee will be regularly updated and consulted on: the progress of the JA and
its WPs, activities of the coordinator at policy level, synergies and activities carried out by the
horizontal WPs 1-4, timely preparation of interim and final reports, as well as regular updating
on financial expenditure of the JA by WPs and individual partners, where problematic.
6.3.3 General Assembly (GA)
In addition to the rules described in Section 6.2, the following rules apply:
6.3.3.1 Members
General Assembly (GA) meetings consisting of representatives of all Associated Partners and the
PMT, with Collaborating Partners and possibly other related projects and initiatives invited.
The Coordinator shall chair all meetings of the General Assembly.
6.3.3.2 Tasks
- General Assembly meetings will be held to discuss progress on Joint Action objectives with the
entire Associated Partner consortium.
6.3.4 Policy decision making forum (PDMF)
In addition to the rules described in Section 6.2, the following rules apply:
6.3.4.1 Members
Policy decision making forum (PDMF) shall consist of the representatives of DG Santé, DG-Agri, DG
Connect, DG Research, DG JRC, other relevant DGs, representatives of EU Agencies and bodies such as
EFSA and ERGA, representatives of the EU Parliament, representatives of the current Presidencies, WP
Leaders.
The Coordinator shall chair all meetings of the PDMF.
16
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
6.3.4.2 Tasks
- The Policy decision making forum shall act in synergy with the horizontal Work Packages and
particularly Work Packages 4-7.
- Depending on the nature of the proposals, meeting documents and agenda topics, the Policy
decision making forum PDMF will be asked to provide critical feedback on the feasibility of
implementation at national and EU level, with a view to the achievement of the Joint Action
outcome indicators as set out in the Grant Agreement.
- Policy briefs with EU stakeholders will be produced in order to capitalise on the work of the
PDMF and expedite implementation, this will be done in conjunction with WP 2 and 4 (that
will be responsible for Policy briefs production).
- WP 1 will be responsible for coordinating and preparing the meeting documents for the PDMF.
6.4 Coordinator
6.4.1 The Coordinator shall be the intermediary between the beneficiaries and the Funding Authority
and shall perform all tasks assigned to it as described in the Grant Agreement and in this Consortium
Agreement.
6.4.2 In particular, the Coordinator shall:
- Monitor that the action is implemented properly (see Article 7 of the Grant Agreement);
- Act as the intermediary for all communications between the beneficiaries and the Agency (in
particular, providing the Agency with the information described in Article 12 of the Grant
Agreement), unless the GA specifies otherwise;
- Request and review any documents or information required by the Agency and verify their
completeness and correctness before passing them on to the Agency;
- Submit the deliverables and reports to the Agency (see Articles 14 and 15 of the Grant
Agreement);
- Ensure that all payments are made to the other beneficiaries without unjustified delay (see
Article 16 of the Grant Agreement);
- Inform the Agency of the amounts paid to each beneficiary, when required in the Grant
Agreement (see Articles 28 and 34) or requested by the Agency, or in the context of ex post
Audits.
6.4.3 The Coordinator shall not be entitled to act or to make legally binding declarations on behalf of
any other beneficiary or of the consortium, unless explicitly stated otherwise in the Grant Agreement
or this Consortium Agreement, or unless it is expressly agreed in written form.
17
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
6.4.4 The Coordinator shall not enlarge its role beyond the tasks specified in this Consortium
Agreement and in the Grant Agreement.
Section 7: Financial provisions
7.1 General Principles
7.1.1 Justifying Costs
In accordance with its own usual accounting and management principles and practices, each
beneficiary shall be solely responsible for justifying its costs with respect to the Joint Action towards
the Coordinator and/or Funding Authority. Each beneficiary will establish the necessary legal,
administrative and/or operational arrangements with their affiliated entities to ensure the correct
justification of the costs incurred.
The Coordinator is an intermediary between the beneficiaries and the Funding Authority. The
Coordinator is responsible for passing on to beneficiaries any claims the Funding Authority might have
in respect of the Grant Agreement, and supplying all the required documents and information to the
Funding Authority.
Beneficiaries shall certify that the information provided in their financial reports to the Funding
Authority (via the Coordinator) is full, reliable and true. They shall also certify that the costs incurred
are eligible in accordance with Article 6 of the Grant Agreement.
There will be 6 internal interim financial reports, each covering a period of 6 months. Internal interim
financial report should be sent to the Coordinator by each beneficiary within 1 month after the related
reporting period.
Nr. of report Reporting period Due date
M1-M6 M8
Report 1
(October 2020 – March 2021) (May 2021)
M7-M12 M13
Report 2
(April 2021 – September 2021) (October 2021)
M13-M18 M19
Report 3
(October 2021 – March 2022) (April 2022)
M19-M24 M25
Report 4
(April 2022 – September 2022) (October 2022)
M25-M30 M31
Report 5
(October 2022 – March 2023) (April 2023)
M19-M36 M37
Report 6
(April 2023 – September 2023) (October 2023)
18
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Financial and technical reporting to the Funding Authority consists of two reports:
Report Reporting period
M1 – M18 (October 2020 – March 2022)
INTERIM REPORT
FINAL REPORT M19 – M36 (April 2022 – September 2023)
All beneficiaries should submit all reports according to the instructions set in the Grant Agreement.
The Coordinator must review and explicitly approve the Interim and Final reports before submission
to Funding Authority. Interim and Final Reports are submitted to Funding Authority by the Coordinator
within 60 days following the end of each reporting period (M1-18 and M19-36).
7.1.2 Funding Principles
A beneficiary which spends less than its allocated share of the budget as set out in the Grant
Agreement will be funded in accordance with its actual duly justified eligible costs only.
A beneficiary that spends more than its allocated share of the budget as set out in the Grant Agreement
will be funded only in respect of duly justified eligible costs up to an amount not exceeding that share,
unless otherwise agreed with the Funding Authority.
7.1.3 Financial Consequences of the termination of the participation of a beneficiary
A beneficiary leaving the consortium shall refund all payments it has received except for the work
contribution approved by the Funding Authority. Furthermore, a Defaulting beneficiary shall bear any
reasonable and justifiable additional costs occurring to the other beneficiaries in order to perform its
and their tasks.
7.2 Payments
7.2.1 Payment schedule
The payment schedule, which contains the transfer of pre-financing, interim and final payments to
beneficiaries, will be handled according to the Article 16 of the Grant Agreement.
Funding of costs included in the Grant Agreement will be paid to beneficiaries after receipt from the
Funding Authority in separate instalments as agreed below:
100% on receipt of Advance Payment (pre-payment)
Interim payment reimburses the eligible costs incurred for the implementation of the action
during the corresponding reporting period. Limit to 90% of the maximum grant amount.
Payment of the balance, on the basis of the request for payment of the balance
19
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Funding for costs accepted by the Funding Authority will be paid to the beneficiary concerned.
The Coordinator is entitled to withhold any payments due to a beneficiary identified by the Steering
Committee to be in breach of its obligations under this Consortium Agreement or the Grant
Agreement. The Coordinator is equally entitled to withhold payments to a beneficiary, in accordance
with circumstances, described in Article 5.3.4, 5.4, 27.2 and 28 of the Grant Agreement or when this is
suggested by or agreed with the Funding Authority. The Coordinator will inform each such beneficiary
about the reasons for withholding funds and release terms.
The Coordinator is entitled to recover any payments already paid to a Defaulting beneficiary. Each
beneficiary’s responsibility in case of recovery of undue amounts is limited to its own debts. Undue
amounts paid by Funding Authority for costs declared by an affiliated entity will be considered as
amounts unduly paid to the beneficiary concerned.
The Coordinator will inform each such beneficiary about the procedure of the recovery of the
amounts:
with detailed information about the reasons for the recovery and the amount due;
with a debit note with the terms and the date of the payment.
7.2.2 Payments from Funding Authority to beneficiaries are the exclusive tasks of the Coordinator
The financial contribution of the Joint Action should be distributed by the Coordinator to beneficiaries
according to:
• the approval of reports by Funding Authority; and
• the provisions of payments in the Grant Agreement.
The Coordinator will transfer the financial contributions to the beneficiaries, including the financial
contributions of their affiliated entities, within 30 calendar days from receipt of transfer. Beneficiaries
should transfer received financial contributions for their affiliated entities without unjustified delay.
Beneficiaries should provide the Coordinator with updated financial information on bank transfer
details in a timely manner.
Section 8: Results
8.1 Ownership of results
Unless stipulated otherwise in the Grant Agreement, ownership of the results of the JA, including both
intellectual property rights and of the reports and documents relating to it, shall be vested in the
beneficiaries.
Foreground resulting from the JA shall be owned by the beneficiary generating it. When Foreground is
generated jointly, it shall be jointly owned, unless the beneficiaries in question agree on a different
solution.
20
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Unless otherwise agreed:
- each of the joint owners shall be entitled to use their jointly owned Results for non-commercial
research activities on a royalty-free basis, and without requiring the prior consent of the other joint
owner(s), and
- each of the joint owners shall be entitled to otherwise Exploit the jointly owned Results and to grant
non-exclusive licenses to third parties (without any right to sub-license), if the other joint owners are
given:
a) at least 45 calendar days advance notice with a right for the other joint owners to object hereto
at the latest 15 days after receipt of such notice; and
b) if no objection is made within the time limit stated above, the permission is given by the other
joint owners who each shall receive Fair and Reasonable compensation taking into account
each joint owner's relative contribution to the jointly owned Results.
However, the joint owners shall, as soon as possible after the creation of the joint Results enter into a
Joint Ownership Management Agreement to agree on all protection measures, ownership percentages
and the division of related costs in advance.
8.2 Transfer of Results
8.2.1 Each beneficiary may transfer ownership of its own Results. It must however ensure that its
obligation under the Grant Agreement and this Consortium Agreement also apply to the new owner
and that this owner has the obligation to pass them on in any subsequent transfer.
8.2.2 Unless otherwise agreed in writing for specifically-identified Third Parties or unless
impossible under applicable EU and national laws on mergers and acquisitions, a Party that intends
to transfer ownership of results must give at least 45 days advance notice (or less if agreed in writing)
to the other beneficiaries that still have (or still may request) access rights to the results. This
notification must include sufficient information on the new owner to enable any beneficiary
concerned to assess the effects on its access rights.
Unless otherwise agreed in writing for specifically-identified Third Parties, any beneficiary may object
within 30 days of receiving notification (or less if agreed in writing), if it can show that the transfer
would adversely affect its Access rights. In this case, the transfer may not take place until agreement
has been reached between the beneficiaries concerned.
8.2.3 The obligations above apply only for as long as other beneficiaries still have - or still may
request - Access Rights to the Results.
8.3 Dissemination
8.3.1 For the avoidance of doubt, nothing in this Section 8.4 has impact on the confidentiality
obligations set out in Section 10.
8.3.2 Dissemination of own Results
The beneficiaries acknowledge their common interest in publishing Results to obtain recognition
within the scientific community and to advance the state of scientific knowledge in their scientific field.
21
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
It is contemplated that the Results will jointly be published whenever applicable, notably in the respect
of the fact that one such Result is jointly-owned; however, the beneficiaries each separately reserve
the right to publish their own Results and Background. Authorship on joint publications will be based
on academic standards and customs.
The beneficiary(ies) wishing to make a publication or communication will provide a copy of such
proposed abstract or publication manuscript (and a reasonably detailed description of any such oral
presentation or other public disclosure) to all the beneficiaries concerned via the Coordinator, at least
fifteen (15) days prior to any submission of publication or communication to an editor.
Following the above notification, a beneficiary may object within fifteen (15) days to the proposed
publication or communication.
An objection is justified if
(a) the protection of the objecting beneficiary's Results or Background would be adversely affected
(b) the objecting beneficiary 's legitimate interests in relation to the Results or Background would be
significantly harmed
(c) the publication contains Confidential Information of the objecting beneficiary.
The objection has to include a precise request for necessary modifications.
Beneficiaries who fail to answer within fifteen (15) calendar days will be considered to have given their
consent.
Provided that all reasonable modifications have been implemented, none of the beneficiaries
concerned may withhold its consent to publication or communication for a period longer than six (6)
months from the date such publication or communication was first notified to the Parties.
If an objection has been raised the involved beneficiaries shall discuss how to overcome the justified
grounds for the objection in a timely basis (for example by amendment to the planned publication
and/or by protecting information before publication) and the objecting beneficiary shall not
unreasonably continue the opposition if appropriate measures are taken following the discussion.
8.3.3 Information on EU FUNDING – Obligation and right to use the EU emblem
All dissemination connected to the Joint Action must:
- display the EU emblem (when displayed in association with another logo, the EU emblem must have
appropriate prominence) and
- include the following text:
“This [insert appropriate description, e.g. report, publication, conference, infrastructure, equipment,
insert type of result, etc.] was funded by the European Union’s Health Programme (2014-2020).”
All dissemination connected to the Joint Action must stipulate that they arise from the Best-ReMaP
Joint Action and include one of the appropriate Joint Action logos in a prominent place.
22
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Publications should also include the following disclaimer: "The content of this [insert appropriate
description, e.g. report, publication, conference, etc.] represents the views of the author only and is
his/her sole responsibility; it cannot be considered to reflect the views of the European Commission
and/or the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) or any other body of
the European Union. The European Commission and the Agency do not accept any responsibility for
use that may be made of the information it contains.”
8.3.4 Dissemination of another beneficiary’s unpublished Results or Background
A beneficiary shall not include in any dissemination activity another beneficiary's Results or
Background without obtaining the owning beneficiary 's prior written approval, unless they are already
published. The mere absence of an objection is not considered as an approval.
8.3.5 Use of names, logos or trademarks
Nothing in this Consortium Agreement shall be construed as conferring rights to use in advertising,
publicity or otherwise the name of the beneficiaries or any of their logos or trademarks without their prior
written approval.
Section 9: Access Rights
9.1 Background included
9.1.1 In Attachment 1, the beneficiaries have identified and agreed on the Background for the Project
and have also, where relevant, informed each other that Access to specific Background is subject to legal
restrictions or limits.
Anything not identified in Attachment 1 shall not be the object of Access Right obligations regarding
Background.
9.1.2 Any beneficiary can propose to the Coordinator to modify its Background in Attachment 1.
However, approval of the Steering Committee is needed should a beneficiary wish to remove or
modify Background in Attachment 1.
For avoidance of doubt, under no circumstances should the withdrawal of any Background impair
implementation of the Joint Action.
9.2 General Principles
9.2.1 Each beneficiary shall implement its tasks in accordance with the Grant Agreement and shall
bear sole responsibility for ensuring that its acts within the Joint Action do not knowingly infringe Third
Party property rights.
9.2.2 Any Access Rights granted expressly exclude any rights to sublicense unless expressly stated
otherwise.
9.2.3 Access Rights Needed for the performance of the work of a beneficiary under the Joint Action
shall be free of any administrative transfer costs.
23
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
9.2.4 Access Rights are granted on a non-exclusive basis.
9.2.5 Results and Background shall be used only for the purposes for which Access Rights to it have
been granted.
9.2.6 All requests for Access Rights shall be made in writing. The granting of Access Rights may be
made conditional on the acceptance of specific conditions aimed at ensuring that these rights will be
used only for the intended purpose and that appropriate confidentiality obligations are in place.
9.2.7 The requesting beneficiary must show that the Access Rights are Needed.
9.3 Access Rights for implementation
Access Rights to Results and Background Needed for the performance of the own work of a beneficiary
under the Joint Action shall be granted on a royalty-free basis, unless otherwise agreed for Background
in Attachment 1.
9.4 Access Rights for Exploitation
9.4.1 Access Rights to Background if Needed for Exploitation of a beneficiary’s own Results, shall be
granted on Fair and Reasonable conditions.
9.4.2 Access Rights to Results if Needed for Exploitation of a beneficiary 's own Results shall be
granted on Fair and Reasonable conditions. Access rights to Results for internal research activities shall
be granted on a royalty-free basis.
9.4.3 A request for Access Rights may be made up to twelve months after the end of the Project or,
in the case of Section 9.7.1.2 of this Consortium Agreement after the termination of the requesting
beneficiary’s participation in the Joint Action.
9.5 Access Rights for affiliated entities
Affiliated entities have Access Rights under the conditions of the Grant Agreement Article 19.
Such Access Rights must be requested by the affiliated entity from the beneficiary that holds the
Background or Results. Alternatively, the beneficiary granting the Access Rights may individually agree
with the beneficiary requesting the Access Rights to have the Access Rights include the right to
sublicense to the latter's affiliated entities listed in Article 11.1.1 of the Grant Agreement. Access Rights
to affiliated entities shall be granted on Fair and Reasonable conditions and upon written bilateral
agreement.
Affiliated entities which obtain Access Rights in return fulfil all confidentiality and other obligations
accepted by the beneficiaries under the Grant Agreement or this Consortium Agreement as if such
affiliated entities were beneficiaries.
Access Rights may be refused to affiliated entities if such granting is contrary to the legitimate interests
of the beneficiary which owns the Background or the Results.
24
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Access Rights granted to any affiliated entity are subject to the continuation of the Access Rights of the
beneficiary to which it is affiliated, and shall automatically terminate upon termination of the Access
Rights granted to such beneficiary.
Upon cessation of the status as an affiliated entity, any Access Rights granted to such former affiliated
entity shall lapse.
Further arrangements with affiliated entities may be negotiated in separate agreements.
9.6 Additional Access Rights
The Beneficiaries agree to negotiate in good faith any additional Access Rights to Results as might be
asked for by any beneficiary, upon adequate financial conditions to be agreed.
9.7 Access Rights for beneficiaries leaving the consortium
9.7.1 Access Rights granted to a beneficiary leaving the consortium
9.7.1.1 Defaulting beneficiary
Access Rights granted to a Defaulting beneficiary and such beneficiary's right to request Access Rights
shall cease immediately upon receipt by the Defaulting beneficiary of the formal notice of the decision
of the Steering Committee to terminate its participation in the consortium.
9.7.1.2 Non-defaulting beneficiary
A non-defaulting beneficiary leaving voluntarily and with the other beneficiaries' consent shall have
Access Rights to the Results developed until the date of the termination of its participation.
It may request Access Rights within the period of time specified in Section 9.4.3.
9.7.2 Access Rights to be granted by any leaving beneficiary
Any beneficiary leaving the Joint Action shall continue to grant Access Rights pursuant to the Grant
Agreement and this Consortium Agreement as if it had remained a beneficiary for the whole duration
of the Joint Action.
Section 10: Data protection and data management
10.1 General Data Protection Regulation
Each beneficiary will comply with the General Data Protection Regulation (Regulation (EU) 2016/679),
hereinafter “GDPR”, and with the national data protection laws where relevant. All used or collected
data will be shared in anonymized or pseudonymized format.
Each beneficiary stays responsible for the lawfulness of the data in accordance with GDPR and any
national data protection laws where relevant, therefore the primary responsibility will stay with the
Data Protection Officers of the beneficiaries.
25
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Each beneficiary is aware that anonymization of data is never final and that re-identification is a real
risk. Therefore, each beneficiary undertakes to implement technical and legal measures according to
the applicable European and National laws to ensure a lawful basis for every data processing and to
safeguard the rights of the individuals.
10.2 Informed consent procedures for the collection and storage of personal data
Unless otherwise provided, the processing of the personal data is only lawful if the data subject has
given consent to the processing for one or more specific purposes. Each beneficiary undertakes to
ensure that the data subject is aware of the fact that and the extent to which consent is given.
Section 11: Non-disclosure of information
11.1
All information in whatever form or mode of communication, which is disclosed by a beneficiary (the
“Disclosing beneficiary”) to any other beneficiary (the “Recipient”) in connection with the Joint Action
during its implementation and which has been explicitly marked as “confidential” at the time of disclosure,
or when disclosed orally has been identified as confidential at the time of disclosure and has been
confirmed and designated in writing within 15 calendar days from oral disclosure at the latest as
confidential information by the Disclosing beneficiary, is “Confidential Information”.
11.2
The Recipients hereby undertake in addition and without prejudice to any commitment on non-disclosure
under the Grant Agreement, for a period of 5 years after the end of the Project:
- not to use Confidential Information otherwise than for the purpose for which it was disclosed;
- not to disclose Confidential Information without the prior written consent by the Disclosing
beneficiary;
- to ensure that internal distribution of Confidential Information by a Recipient shall take place
on a strict need-to-know basis; and
- to return to the Disclosing Party, or destroy, on request all Confidential Information that has
been disclosed to the Recipients including all copies thereof and to delete all information
stored in a machine readable form to the extent practically possible. The Recipients may keep
a copy to the extent it is required to keep, archive or store such Confidential Information
because of compliance with applicable laws and regulations or for the proof of on-going
obligations provided that the Recipient comply with the confidentiality obligations herein
contained with respect to such copy for as long as the copy is retained.
11.3
The Recipients shall be responsible for the fulfilment of the above obligations on the part of their
employees or third parties involved in the Joint Action and shall ensure that they remain so obliged, as
far as legally possible, during and after the end of the Joint Action and/or after the termination of the
contractual relationship with the employee or third party.
26
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
11.4
The above shall not apply for disclosure or use of Confidential Information, if and in so far as the Recipient
can show that:
- the Confidential Information becomes publicly available by means other than a breach of the
Recipient’s confidentiality obligations;
- the Disclosing beneficiary subsequently informs the Recipient that the Confidential
Information is no longer confidential;
- the Confidential Information is communicated to the Recipient without any obligation of
confidentiality by a third party who is to the best knowledge of the Recipient in lawful
possession thereof and under no obligation of confidentiality to the Disclosing beneficiary;
- the disclosure or communication of the Confidential Information is foreseen by provisions of
the Grant Agreement;
- the Confidential Information, at any time, was developed by the Recipient completely
independently of any such disclosure by the Disclosing beneficiary; or
- the Confidential Information was already known to the Recipient prior to disclosure, or
- the Recipient is required to disclose the Confidential Information in order to comply with
applicable laws or regulations or with a court or administrative order, subject to the provision
Section 10.7 hereunder.
11.5
The Recipient shall apply the same degree of care with regard to the Confidential Information disclosed
within the scope of the Joint Action as with its own confidential and/or proprietary information, but in no
case less than reasonable care.
11.6
Each beneficiary shall promptly advise the other beneficiary in writing of any unauthorised disclosure,
misappropriation or misuse of Confidential Information after it becomes aware of such unauthorised
disclosure, misappropriation or misuse.
11.7
If any beneficiary becomes aware that it will be required, or is likely to be required, to disclose Confidential
Information in order to comply with applicable laws or regulations or with a court or administrative order,
it shall, to the extent it is lawfully able to do so, prior to any such disclosure:
- notify the Disclosing beneficiary, and
- comply with the Disclosing beneficiary’s reasonable instructions to protect the confidentiality
of the information.
27
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 12: Miscellaneous
12.1 Attachments, inconsistencies and severability
This Consortium Agreement consists of this core text and
Attachment 1 (Background included)
Attachment 2 (Accession document)
In case the terms of this Consortium Agreement are in conflict with the terms of the Grant Agreement,
the terms of the latter shall prevail. In case of conflicts between the attachments and the core text of this
Consortium Agreement, the latter shall prevail.
Should any provision of this Consortium Agreement become invalid, illegal or unenforceable, it shall not
affect the validity of the remaining provisions of this Consortium Agreement. In such a case, the
beneficiaries concerned shall be entitled to request that a valid and practicable provision be negotiated
which fulfils the purpose of the original provision.
12.2 No representation, partnership or agency
Except as otherwise provided in Section 6.4.3, no beneficiary shall be entitled to act or to make legally
binding declarations on behalf of any other beneficiary or of the consortium. Nothing in this Consortium
Agreement shall be deemed to constitute a joint venture, agency, partnership, interest grouping or any
other kind of formal business grouping or entity between the beneficiaries.
12.3 Notices and other communication
Any notice to be given under this Consortium Agreement shall be in writing to the addresses and recipients
as listed in the most current address list kept by the Coordinator.
Formal notices:
If it is required in this Consortium Agreement that a formal notice, consent or approval shall be given, such
notice shall be signed by an authorised representative of a beneficiary and shall either be served
personally or sent by mail with recorded delivery or e-mail or telefax with receipt acknowledgement.
Other communication:
E-mail (where applicable or necessary with acknowledgement of receipt) fulfils the conditions of written
form.
Any change of persons or contact details shall be notified promptly by the respective beneficiary to the
Coordinator. The address list shall be accessible to all beneficiaries.
28
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
12.4 Assignment and amendments
No rights or obligations of the beneficiaries arising from this Consortium Agreement may be assigned
or transferred, in whole or in part, to any third party without the other beneficiaries’ prior formal
approval.
12.5 Mandatory national law
Nothing in this Consortium Agreement shall be deemed to require a beneficiary to breach any mandatory
statutory law under which the beneficiary is operating.
12.6 Language
This Consortium Agreement is drawn up in English, which language shall govern all documents, notices,
meetings, arbitral proceedings and processes relative thereto.
12.7 Applicable law
This Consortium Agreement shall be construed in accordance with and governed by the applicable EU law
supplemented if necessary by the laws of Belgium excluding its conflict of law provisions.
12.8 Settlement of disputes
The beneficiaries shall endeavour to settle their disputes amicably.
A dispute between any beneficiaries of the Consortium agreement will be brought into attention of
the Steering Committee which will act as a mediator and propose solutions to be agreed by the
beneficiaries. The Coordinator will mediate disputes between SC members. Disputes between the
Coordinator and any other beneficiary shall primarily be settled through negotiation.
Nothing in this Consortium Agreement shall limit the beneficiaries' right to seek injunctive relief in any
applicable competent court. Article 41 of the Grant Agreement will be used for unsettled disputes
related to the subject-matter referred to in paragraph 2, Article 41 of the Grant Agreement.
Section 13: Signatures
The beneficiaries have caused this Consortium Agreement to be duly signed by their authorised
representatives in as many separate signature pages per beneficiary as there are beneficiaries, the day
and year first above written. The beneficiaries agree that digital signatures (with registered digital
certificate), and original signatures transmitted via PDF shall be treated as original signatures.
29
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
1. NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ)
Signature:
Name: Milan Krek, MD, Specialist in Public health
Title: Director
Date:
30
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
2. BUNDESMINISTERIUM FUER SOZIALES, GESUNDHEIT, PFLEGE UND KONSUMENTENSCHUTZ
(BMSGPK)
Signature:
Name: Katharina Reich
Title: Dr. med. univ.
Date:
31
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
3. SCIENSANO (SCIENSANO)
Signature:
Name: Prof. Christian Léonard
Title: General manager
Date:
32
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
4. MINISTRY OF CIVIL AFFAIRS (MCA)
Signature:
Name: Mirna Pavlović
Title: Assistant Minister
Date:
33
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
5. NATSIONALEN CENTAR PO OBSHTESTVENO ZDRAVE I ANALIZI (NCPHA)
Signature:
Name: Assoc. Prof. Hristo Hinkov, MD, PhD
Title: Director
Date:
34
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
6. HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO (CIPH)
Signature:
Name: Asst. Prof. Krunoslav Capak, MD, PhD
Title: Director - General
Date:
35
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
7. Ministry of Health of the Republic of Cyprus (MoH CY)
Signature:
Name: Dr. Olga Kalakouta
Title: Chief Health Officer
Date:
36
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
8. FODEVARESTYRELSEN (DVFA)
Signature:
Name: Per Preisler Christiansen
Title: Deputy Director General (Innovation)
Date:
37
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
9. SOTSIAALMINISTEERIUM (MoSA)
Signature:
Name: Marika Priske
Title: Secretary General
Date:
38
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
10. TERVEYDEN JA HYVINVOINNIN LAITOS (THL)
Signature:
Name: Markku Tervahauta
Title: Director general
Date:
39
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
11. AGENCE NATIONALE DE SECURITE SANITAIRE DE L ALIMENTATION DE L ENVIRONNEMENT ET DU
TRAVAIL (ANSES)
Signature:
Name: Roger GENET
Title: Director General
Date:
40
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
12. MAX RUBNER INSTITUT BUNDESFORSCHUNGSINSTITUT FUR ERNAEHRUNG UND LEBENSMITTEL
(MRI)
Signature:
Name: Prof. Dr. Pablo Steinberg
Title: President
Date:
41
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
13. INSTITOUTON YGEIAS TOU PAIDIOU (ICH)
Signature:
Name: Christina Kanaka-Gantenbein, MD, PhD, FMH (CH)
Title: Professor and Chair
First Department of Pediatric
Medical School, National and Kapodistrian University of Athens
Date:
42
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
14. SEMMELWEIS EGYETEM (SU)
Signature:
Name: Béla Dr. Merkely
Title: Rector
Date:
Signature:
Name: Dr. Lívia Pavlik
Title: Chancellor
Date:
Countesigned by:
Signature:
Name: Irén Baumgartnerné Holló
Title: Director General of Economic Management
Date:
43
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
15. DEPARTMENT OF HEALTH (DoH)
Signature:
Name: Dr. Seamus O'Reilly
Title:
Date:
44
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
16. ISTITUTO SUPERIORE DI SANITA (ISS)
Signature:
Name: Prof. Silvio Brusaferro
Title: President
Date:
45
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
17. SLIMIBU PROFILAKSES UN KONTROLES CENTRS (CDPC)
Signature:
Name: Iveta Gavare
Title: Director
Date:
46
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
18. LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA (LR SAM)
Signature:
Name: Ieva Gudanaviciene
Title: Chief Specialist
Date:
47
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
19. Ministry for Health - Government of Malta (MFH)
Signature:
Name: Joseph Rapa
Title: Permanent Secretary
Date:
48
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
20. RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU (RIVM), and on behalf of the Minister of
Health, Welfare and Sport,
Signature:
Name: Prof. dr. ir. J. Brug
Title: Director-General
Date:
49
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
21. SLASKI UNIWERSYTET MEDYCZNY W KATOWICACH (SUM)
Signature:
Name: prof. Tomasz Szczepański
Title: Rector of Medical University of Silesia (SUM)
Date:
50
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
22. MINISTERIO DA SAUDE - REPUBLICA PORTUGUESA (DGS)
Signature:
Name: Graça Freitas
Title: Director-General
Date:
51
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
23. INSTITUTUL NATIONAL DE SANATATE PUBLICA (NIPH)
Signature:
Name: Dr. Radu Cucuiu
Title: General Director
Date:
52
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Section 13: Signatures
AS WITNESS:
The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned
authorised representatives in separate signature pages the day and year first above written.
24. INSTITUT ZA ZASTITU ZDRAVLJA SRBIJEDR MILAN JOVANOVIC BATUT (IPHS)
Signature:
Name: Verica Jovanovic, MD, MSc, PhD, Associate Professor
Title: Acting Director
Date:
53
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Attachment 1: Background included
Background means any data, know-how or information — whatever its form or nature (tangible or
intangible), including any rights such as intellectual property rights — that:
(a) is held by the beneficiaries before they acceded to the Agreement, and
(b) is needed to implement the action or exploit the results.
Because of this need, Access Rights have to be granted in principle, but beneficiaries must identify and
agree amongst them on the Background for the Joint Action. This is the purpose of this attachment.
BENEFICIARY 11
As to AGENCE NATIONALE DE SECURITE SANITAIRE DE L ALIMENTATION DE L ENVIRONNEMENT ET DU
TRAVAIL (ANSES), it is agreed between the beneficiaries that, to the best of their knowledge,
The following background is hereby identified and agreed upon for the Joint Action. Specific limitations
and/or conditions, shall be as mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
Access is granted to all such For the avoidance of doubt For the avoidance of doubt
Background belonging to ANSES does not include ANSES does not include
ANSES that is necessary for Background that is: Background that is:
ANSES to perform its duties • generated by researchers • generated by researchers
as provided for under the not participating in the Action. not participating in the Action.
Best-ReMaP Grant Agreement • generated by researchers • generated by researchers
only participating in the Action, but participating in the Action, but
and for the duration of the in parallel with the Action and in parallel with the Action and
Action only. Access to certain outside the scope of the outside the scope of the
Background and/or Materials Action. Action.
may also be subject to special • subject to any other kind of • subject to any other kind of
conditions. intellectual property protection intellectual property protection
as well as any current as well as any current
applications for such applications for such
protection. protection.
• Background to which • Background to which
ANSES, due to mandatory law ANSES, due to mandatory law
and/or any third party rights, is and/or any third party rights, is
unable to grant Access rights. unable to grant Access rights.
This represents the status at the time of signature of this Consortium Agreement.
54
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
BENEFICIARY 12
As to Max Rubner-Institut, it is agreed between the beneficiaries that, to the best of their knowledge,
The following background is hereby identified and agreed upon for the Joint Action. Specific limitations
and/or conditions, shall be as mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
Metadata on branded food Implementation on metadata Exploitation on metadata provided
evaluated from product monitoring, provided that rights of third parties that rights of third parties are not
carried out by the MRI; current are not affected. affected.
version: June 2020 No implementation on raw data No exploitation on raw data from
from product management. product management.
This represents the status at the time of signature of this Consortium Agreement.
BENEFICIARY 16
As to ‘ISTITUTO SUPERIORE DI SANITA’, it is agreed between the beneficiaries that, to the best of their
knowledge,
The following background is hereby identified and agreed upon for the Joint Action. Specific limitations
and/or conditions, shall be as mentioned hereunder:
Describe Background Specific limitations and/or Specific limitations and/or
conditions for implementation conditions for Exploitation
Istituto Superiore di Sanità (ISS) Access right to Background is only Access right to Background is only
hereby grants Access Rights to granted to the extent that it is granted to the extent that said
Background generated by the ISS needed to implement the tasks Background is not subject to terms
specific research group directly under the action and conditions in other
involved in the Best-ReMaP JA agreements. Access to certain
Background and/or Material may
be subject to special conditions
(MTA, term of use, etc.)
This represents the status at the time of signature of this Consortium Agreement.
55
Best-ReMaP JA Consortium Agreement
Best-ReMaP JA Consortium Agreement 31st of May 2021
Attachment 2: Accession document
ACCESSION
of a new beneficiary to
Best-ReMaP JA Consortium Agreement, version MAY 2021
[OFFICIAL NAME OF THE NEW BENEFICIARY AS IDENTIFIED IN THE Grant Agreement]
hereby consents to become a beneficiary to the Consortium Agreement identified above and accepts all
the rights and obligations of a beneficiary starting [date].
NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ)
hereby certifies that the consortium has accepted in the meeting held on [date] the accession of [the name
of the new beneficiary] to the consortium starting [date].
This Accession document has been done in 2 originals to be duly signed by the undersigned authorised
representatives.
[Date and Place]
[INSERT NAME OF THE NEW BENEFICIARY]
Signature(s)
Name(s)
Title(s)
[Date and Place]
NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ)
Signature(s)
Name(s)
Title(s)
56
Best-ReMaP JA Consortium Agreement